Skip to main content
Premium Trial:

Request an Annual Quote

As Expected, Nasdaq Says Tripos is 'Shell,' Threatens Delisting

NEW YORK (GenomeWeb News) — Nasdaq has notified Tripos that it can be delisted from the Nasdaq Global Market and from the Nasdaq Stock Market because it has become a “public shell” after selling its Discovery Research and Discovery Informatics branches.
Tripos, which said it has been anticipating the notice, said it will meet with the exchange June 28 to review the matter.
Tripos has been executing a liquidation plan since last year. Nasdaq said it may delist the company because Tripos “is not currently engaged in an active business operation” and is now a public shell.
Tripos said today it is “actively engaged” in trying to have its stock listed on the OTC Bulletin Board after Nasdaq delists it.
If that option fails Tripos said it will close its stock transfer books.
The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.